Echo Biotech completes nearly RMB 100M Series B financing to advance next-generation exosome regenerative therapies and systemic anti-aging solutions
Echo Biotech has completed a nearly RMB 100 million Series B round, led again by Zhongbo Juli with participation from Guosheng Capital, to accelerate development of next-generation exosome regenerative therapies and systemic anti-aging solutions.
Quick Facts
- Date: 2025-11-06
- Author: Echo Biotech
FAQ
- What does the Echo Biotech completes nearly RMB 100M Series B financing to advance next-generation exosome regenerative therapies and systemic anti-aging solutions page cover?
- Echo Biotech has completed a nearly RMB 100 million Series B round, led again by Zhongbo Juli with participation from Guosheng Capital, to accelerate development of next-generation exosome regenerative therapies and systemic anti-aging solutions.
- What key information is available on the Echo Biotech completes nearly RMB 100M Series B financing to advance next-generation exosome regenerative therapies and systemic anti-aging solutions page?
- Key information includes: Date: 2025-11-06; Author: Echo Biotech.
- How can customers follow up after reviewing the Echo Biotech completes nearly RMB 100M Series B financing to advance next-generation exosome regenerative therapies and systemic anti-aging solutions page?
- Customers can use the page content, resources, or contact information to discuss products, services, technology platforms, or collaboration needs with Echo Biotech.